Susquehanna International Group
ABEO icon

Susquehanna International Group’s Abeona Therapeutics ABEO Stock Holding History

Susquehanna International Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
292,400
+214,500
+275% +$1.07M ﹤0.01% 7213
2025
Q4 		$411K Sell
77,900
-289,100
-79% -$1.46M ﹤0.01% 9244
2025
Q3 		$1.94M Sell
367,000
-462,500
-56% -$2.93M ﹤0.01% 5859
2025
Q2 		$4.71M Buy
829,500
+799,300
+2,647% +$4.55M ﹤0.01% 4077
2025
Q1 		$144K Buy
30,200
+10,400
+53% +$56.6K ﹤0.01% 11263
2024
Q4 		$110K Sell
19,800
-39,200
-66% -$241K ﹤0.01% 11261
2024
Q3 		$373K Buy
59,000
+31,700
+116% +$166K ﹤0.01% 9132
2024
Q2 		$116K Sell
27,300
-11,200
-29% -$57.1K ﹤0.01% 10910
2024
Q1 		$279K Buy
38,500
+7,800
+25% +$49.4K ﹤0.01% 9865
2023
Q4 		$154K Buy
30,700
+12,400
+68% +$54.5K ﹤0.01% 10955
2023
Q3 		$77K Buy
+18,300
New +$69.2K ﹤0.01% 11087
2022
Q1 		– Sell
-600
Closed -$5K – 12872
2021
Q4 		$5K Sell
600
-972
-62% -$17.9K ﹤0.01% 12985
2021
Q3 		$44K Buy
+1,572
New +$50.3K ﹤0.01% 12383
2021
Q2 		– Sell
-3,376
Closed -$159K – 12464
2021
Q1 		$159K Buy
+3,376
New +$186K ﹤0.01% 11608
2020
Q3 		– Sell
-560
Closed -$41K – 10465
2020
Q2 		$41K Sell
560
-1,480
-73% -$102K ﹤0.01% 9797
2020
Q1 		$107K Buy
2,040
+764
+60% +$51K ﹤0.01% 9274
2019
Q4 		$104K Buy
1,276
+312
+32% +$22K ﹤0.01% 9124
2019
Q3 		$54K Sell
964
-628
-39% -$47K ﹤0.01% 9749
2019
Q2 		$190K Sell
1,592
-2,936
-65% -$492K ﹤0.01% 9168
2019
Q1 		$833K Buy
4,528
+3,540
+358% +$633K ﹤0.01% 5359
2018
Q4 		$176K Sell
988
-3,072
-76% -$670K ﹤0.01% 7852
2018
Q3 		$1.3M Sell
4,060
-6,000
-60% -$2.13M ﹤0.01% 4739
2018
Q2 		$4.02M Buy
10,060
+240
+2% +$105K ﹤0.01% 2996
2018
Q1 		$3.52M Buy
9,820
+2,460
+33% +$914K ﹤0.01% 3003
2017
Q4 		$2.92M Sell
7,360
-14,156
-66% -$5.85M ﹤0.01% 3290
2017
Q3 		$9.17M Buy
21,516
+20,824
+3,009% +$5.6M ﹤0.01% 1848
2017
Q2 		$111K Sell
692
-308
-31% -$42K ﹤0.01% 8640
2017
Q1 		$125K Buy
1,000
+492
+97% +$63.5K ﹤0.01% 8292
2016
Q4 		$62K Buy
508
+72
+17% +$11.3K ﹤0.01% 9234
2016
Q3 		$65K Buy
+436
New +$42.6K ﹤0.01% 8063
2015
Q4 		– Sell
-1,344
Closed -$136K – 9344
2015
Q3 		$136K Sell
1,344
-2,784
-67% -$370K ﹤0.01% 8977
2015
Q2 		$522K Buy
+4,128
New +$620K ﹤0.01% 7560

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's ABEO Position: Q1 2026 in Review

Susquehanna International Group reduced its Abeona Therapeutics (ABEO) stake by 38% in Q1 2026, selling an estimated $1.34M and leaving 432,370 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #6263.

Susquehanna International Group first reported a position in ABEO in Q3 2016 and has held it in 27 quarters since. The position peaked at $3.7M in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Susquehanna International Group held 432,370 shares of Abeona Therapeutics worth $1.94M as of Q1 2026.
  • Susquehanna International Group sold 268,918 Abeona Therapeutics shares in Q1 2026, an estimated $1.34M.
  • Abeona Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6263 holding.
  • Susquehanna International Group first reported a position in Abeona Therapeutics in Q3 2016 and has held it in 27 quarters since.
  • Susquehanna International Group's Abeona Therapeutics position peaked at $3.7M in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.